{
    "clinical_study": {
        "@rank": "153224", 
        "acronym": "AP Hybrid", 
        "arm_group": [
            {
                "arm_group_label": "HYBRID-OPEN", 
                "arm_group_type": "Experimental", 
                "description": "Patients are randomized on the schedule; hybrid period and after open period. During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.\nDuring the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
            }, 
            {
                "arm_group_label": "OPEN-HYBRID", 
                "arm_group_type": "Experimental", 
                "description": "Patients are randomized on the schedule: open period and after  hybrid period. During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.\nDuring the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is the evaluate an Artificial Pancreas during 2 months in\n      home setting in Type 1 Diabetic patients"
        }, 
        "brief_title": "Hybrid Artificial Pancreas in Home Setting", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 1 Diabetes Mellitus", 
            "Treatement by Insulin Pump"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "During this study, we propose to assess an Artificial Pancreas in a group of Type 1 diabetic\n      patients who will participate in two study periods of two-month duration with an insulin\n      pump and a Continuous Glucose Monitoring (CGM) device. During one of these periods, called\n      HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time\n      whereas the patient will self manage glucose control with insulin pump and CGM for the rest\n      of the day. During the control period called OPEN Period, patient self management of\n      diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time\n      spent in range when using artificial pancreas in the hybrid period should be observed with a\n      reduction of both hypo and hyperglycemia episodes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 18 et < 70 years old\n\n          2. Having diabetes according to WHO criteria for at least 6 months, and Type 1 diabetes\n             according to ADA criteria\n\n          3. Under basal-bolus insulin therapy using an external insulin pump for at least 3\n             months\n\n          4. BMI < 35 kg/m\u00b2\n\n          5. Willing to wear a CGM device for the whole duration of the study, except during\n             washout period, combined with the DiAs platform during the evening and night-time for\n             2 months\n\n          6. Trained in carbohydrate counting\n\n          7. HbA1c > 7.5 % and < 10%\n\n          8. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication,\n             stability on the medication for at least 1 month prior to study inclusion\n\n          9. Willing to undergo all study procedures\n\n         10. Informed consent signed\n\n        Exclusion criteria:\n\n          1. Pregnancy or breast feeding, or intention to be pregnant during the study duration\n\n          2. Use of a medication that significantly impacts glucose metabolism, e.g. steroids\n\n          3. Uncontrolled hypertension with resting blood pressure over 140/90 mmHg\n\n          4. Patient plans to go abroad during the trial period\n\n          5. Patient is expected to be out-of-home in the evening and during night time (e.g.\n             shift-workers, etc.) more than 25% of a study period\n\n          6. Patient does not hold any nearby party for assistance if needed\n\n          7. Patient with severe hypoglycemia including coma, mental confusion and/or convulsions\n             requesting IV glucose injection or glucagon injection during the last year.\n\n          8. Presence of any malignant disease, unless considered as cured for more than 10 years\n\n          9. History of acute cardiovascular event during the prior year\n\n         10. History of diabetic keto-acidosis during the prior 6 months\n\n         11. Renal insufficiency with creatinin > 150 \u03bcmol/L\n\n         12. Impairment of liver status estimated from ASAT/ALAT plasma levels > 2x upper limits\n             of normal values\n\n         13. Impaired cognitive or psychological abilities which may result in defective adherence\n             to study conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153190", 
            "org_study_id": "UF8628 4"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HYBRID-OPEN", 
                    "OPEN-HYBRID"
                ], 
                "description": "During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.", 
                "intervention_name": "HYBRID", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "HYBRID-OPEN", 
                    "OPEN-HYBRID"
                ], 
                "description": "During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.", 
                "intervention_name": "OPEN", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pancreatin", 
                "Pancrelipase"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 1 Diabetes,", 
            "T1DM,", 
            "Artificial Pancreas"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "e-renard@chu-montpellier.fr", 
                    "last_name": "Eric ER RENARD, MD", 
                    "phone": "+33 4 67 33 82 83"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34000"
                    }, 
                    "name": "CHU Montpellier"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cobelli@dei.unipd.it", 
                    "last_name": "Claudio CC COBELLI, MD", 
                    "phone": "+39-049-8277661"
                }, 
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy"
                    }, 
                    "name": "University of Padova"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "J.H.deVries@amc.uva.nl", 
                    "last_name": "Hans HD De Vries, MD", 
                    "phone": "+31 20 5666525"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "University of Amsterdam"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Italy", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of Hybrid Use of an Artificial Pancreas in a Home Setting for Two Months in Patients With Type 1 Diabetes", 
        "overall_contact": {
            "email": "e-renard@chu-montpellier.fr", 
            "last_name": "Eric ER RENARD, MD", 
            "phone": "+33 4 67 33 83 82"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Montpellier", 
            "last_name": "Eric ER RENARD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent time spent in target range (3.9-10.0 mmol/L or 70-180 mg/dL) during each study period", 
            "safety_issue": "No", 
            "time_frame": "during 2 months-hybrid period and during 2 months-open period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153190"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Low Blood Glucose Index (LBGI)", 
            "safety_issue": "No", 
            "time_frame": "for each period of 2 month (hybrid period and open period)"
        }, 
        "source": "University Hospital, Montpellier", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Montpellier", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}